Studies of Rare Cancers
Studies of Rare Cancers
批准号:
10918980
负责人:
Katherine McGlynn
金额:
$102.67万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
AffectAfrica South of the SaharaAlcohol consumptionAlcoholic HepatitisAntidiabetic DrugsAreaAsiaCancer EtiologyCenters for Disease Control and Prevention (U.S.)Developed CountriesDiabetes MellitusEtiologyEuropeHIVHIV/HCVHeavy DrinkingHepatitis CHepatitis C co-infectionHepatitis C virusHistologicIncidenceInfectionIntrahepatic CholangiocarcinomaInvestigationMalignant NeoplasmsMalignant neoplasm of liverNon-Steroidal Anti-Inflammatory AgentsObesityPersonsPharmaceutical PreparationsPrimary Malignant Neoplasm of LiverPrimary carcinoma of the liver cellsResearchRiskRisk FactorsUnited StatesViralfollow-upinsightinterestmortalityrare cancerresearch study
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Primary liver cancer, composed of two major histologic types, hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC), is the sixth most frequently occurring cancer in the world and the second most common cause of cancer mortality. While over 80% of liver cancers occur in Asia and sub-Saharan Africa, incidence has been increasing in low-rate areas, such as the U.S. and Europe, for several decades. Our research has been focusing on identifying factors associated with this increase in incidence. According to the Centers for Disease Control and Prevention (CDC), approximately 25% of people with HIV in the United States also have HCV. Infection with both HIV and HCV is called HIV/HCV coinfection. While excessive alcohol consumption and hepatitis C virus infection are major risk factors, our research has found that the risk attributable to diabetes and obesity is greater than the risk attributable to other factors. To follow-up on these findings, we are examining the contributions of these factors in 2 U.S. based research studies. We are also examining whether medications such as anti-diabetic drugs, non-steroidal anti-inflammatory drugs and statins affect the risk of liver cancer in developed countries.
期刊论文(93)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1002/ijc.29960
发表时间:
2016-05-01
期刊:
International journal of cancer
影响因子:
6.4
作者:
[McGlynn KA, Hagberg K, Chen J, Braunlin M, Graubard BI, Suneja N, Jick S, Sahasrabuddhe VV]
通讯作者:
Sahasrabuddhe VV
DOI:
10.1371/journal.pone.0120574
发表时间:
2015
期刊:
PloS one
影响因子:
3.7
作者:
[Altekruse SF, Petrick JL, Rolin AI, Cuccinelli JE, Zou Z, Tatalovich Z, McGlynn KA]
通讯作者:
McGlynn KA
DOI:
10.1158/1055-9965.epi-13-0712
发表时间:
2013-12
期刊:
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
影响因子:
--
作者:
[Cook MB, Gamborg M, Aarestrup J, Sørensen TI, Baker JL]
通讯作者:
Baker JL
DOI:
10.1002/hep.24397
发表时间:
2011-08
期刊:
HEPATOLOGY
影响因子:
13.5
作者:
[Welzel, Tania M., Graubard, Barry I., Zeuzem, Stefan, El-Serag, Hashem B., Davila, Jessica A., McGlynn, Katherine A.]
通讯作者:
McGlynn, Katherine A.
DOI:
10.1007/s10654-009-9402-3
发表时间:
2009
期刊:
EUROPEAN JOURNAL OF EPIDEMIOLOGY
影响因子:
13.6
作者:
[Andreotti, Gabriella, Menashe, Idan, Chen, Jinbo, Chang, Shih-Chen, Rashid, Asif, Gao, Yu-Tang, Han, Tian-Quan, Sakoda, Lori C., Chanock, Stephen, Rosenberg, Philip S., Hsing, Ann W.]
通讯作者:
Hsing, Ann W.
共 66 条
Studies of Rare Cancers
-
批准号:10702923
-
项目类别:
-
资助金额:$278.97万
-
财政年份:--
-
负责人:Katherine McGlynn
-
依托单位:
Studies of Rare Cancers
-
批准号:10007419
-
项目类别:
-
资助金额:$67.07万
-
财政年份:--
-
负责人:Katherine McGlynn
-
依托单位:
Etiologic Studies of Diet and Cancer
-
批准号:8351078
-
项目类别:
-
资助金额:$41.09万
-
财政年份:--
-
负责人:Katherine McGlynn
-
依托单位:
Studies of Rare Cancers
-
批准号:10263747
-
项目类别:
-
资助金额:$148.98万
-
财政年份:--
-
负责人:Katherine McGlynn
-
依托单位:
Studies of Rare Cancers
-
批准号:9549609
-
项目类别:
-
资助金额:$43.46万
-
财政年份:--
-
负责人:Katherine McGlynn
-
依托单位:
海外基金